Abstract
Introduction
Extensive epidemiological data suggest important roles of type 2 diabetes mellitus (DM2) in carcinogenesis [1] [2] [3] [4] and prognosis [5] . Pancreatic cancer is well documented to be associated with DM2 [6] [7] [8] [9] [10] , and up to 80% of pancreatic cancer patients have overt DM2 or impaired glucose tolerance [11] . Breast cancer is another prevalent cancer among many other cancers that are associated with DM2 [12] , and up to 15% of breast cancer patients have DM2 (i.e 
. about 375,000 in the United States).
Overt DM2 is characterized by hyperglycaemia, hyperinsulinemia and high insulin-like growth factor-1 , and all three characteristics may promote cancer. As demonstrated by glycohaemoglobin levels in cancer patients, elevated average blood glucose may be associated with a higher proportion of patients with active cancer than patients in remission [13] , suggesting that hyperglycaemia may promote cancer progression. Elevations in levels of glucose and free fatty acids in DM2 were also correlated with enhanced tumour growth both in vivo and in vitro [14] . Insulin was reported to stimulate proliferation and glucose utilization in pancreatic cancer cells; insulin augmented DNA synthesis mainly by mitogen-activated protein kinase activation and glucose uptake mainly by phosphoinositide 3-kinase activation and enhancement of glucose transporter-1 expression [15] . Furthermore, IGF-1 was found to prevent apoptosis of cancer cells induced by chemotherapeutic agents leading to chemoresistance in vitro [16] . [17] [18] [19] , and so has metformin [20] [21] [22] , a biguanide that activates AMP-activated protein kinase (AMPK) and decreases signalling through mammalian target of rapamycin (mTOR) [23] . In a population-based cohort study [24] (Fig. 1A) . At a high insulin concentration of 5 g/ml, MiaPaCa2 cells increased proliferation as the glucose concentration increased, but at a normal insulin concentration of 0.0005 g/ml, this effect of glucose was not so obvious (Fig. 1B) . The growth promoting effect of glucose and insulin was confirmed using a different method, counting Trypan blue dye excluding cells under the microscope (Fig. 1C) Fig. 2A ) [26] . (Fig. 4D), indicating that high insulin attenuated the inhibitory effect of gemcitabine. (Fig. 5A) . Indeed, we showed that the combination of rosiglitazone and gemcitabine inhibited proliferation of MiaPaCa2 cells more than gemcitabine alone in four combinations of glucose and insulin (Fig. 5B) . Similar results were obtained with metformin in combination with gemcitabine (Fig. 5C) [27] . Fig. 5D) .
Specific types of pharmacotherapy for DM2 may have different impacts on these mechanisms, thereby having different end results in terms of cancer progression. Current medications for DM2 include thiazolidinediones (e.g. rosiglitazone), biguanides (e.g. metformin), sulfonylureas, meglitinides, ␣-glucosidase inhibitors, amylin analogues, dipeptidyl peptidase-4 inhibitors, incretin mimetics (e.g. exenatide) and insulin preparations. Although all these different classes of medications can lower blood glucose, the mechanisms of actions of these agents are different and they have different impacts on the circulating insulin levels. In addition, some antidiabetic drugs may have direct anti-tumour effects. For example, thiazolidinediones (agonists of peroxisome proliferator-activated receptor-␥) have been shown to suppress various types of cancer cells in cell culture and in animal models
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Glucose and insulin promoted cell proliferation of cancer cells
DM2 is characterized by hyperinsulinemia and hyperglycaemia. MiaPaCa2 cells are known to express insulin and insulin-like growth factor receptors [25]. We showed that the proliferation of MiaPaCa2 cells was accelerated by high glucose and high insulin (Fig. 1). At a high glucose concentration of 4000 mg/l, MiaPaCa2 cells increased proliferation as the insulin concentration increased
We found that metformin and rosiglitazone dose-dependently inhibited MiaPaCa2 cell proliferation in all four combinations of glucose and insulin tested (Fig. 2B and C). Interestingly, exenatide, an analogue of glucagon-like peptide-1, had no direct inhibitory effect on MiaPaCa2 cells at concentrations relevant to the treatment of DM2 (Fig. 2D). To further investigate the effects of these medications in other cancer cell types, breast cancer cell lines HER18 (Fig. 2E) and MCF7 (Fig. 2F) were treated with metformin (20 mM) and rosiglitazone (100 M) in various combinations of glucose and insulin concentrations for 3 days followed by the MTT assay. The 3D plots showed that metformin and rosiglitazone decreased the number of live breast cancer cells in all the combinations of insulin and glucose concentrations tested. Metformin and rosiglitazone also decreased the number of live HER18 and MCF7 cells (MTT assay) in time-and dose-dependent manners whereas exenatide had no effect on these cells (data not shown). Together, these data indicated that metformin and rosiglitazone could directly inhibit the growth activity of human cancer cells whereas exenatide had no such an activity.
Metformin and rosiglitazone induced apoptosis in cancer cells
(D) OD values in the MTT assay of indicated cell lines are plotted along the z-axis versus the insulin (x-axis) and glucose (y-axis) concentrations. Grey-scale shading represents OD value according to the key.
Fig. 2 Rosiglitazone and metformin suppress proliferation of cancer cells. (A) The stages in the natural history of DM2 are determined by the loss of ␤ cell function over time. The characteristics of glucose and insulin levels are listed in the table above the diagram, which has been redrawn based on data from the UK Prospective Diabetes Study 16 [26]. MiaPaCa2 cells were cultured for 3 days in media containing different concentrations of glucose and insulin, and were treated with different concentrations of metformin (B), rosiglitazone (C) and exenatide (D). The OD values in the MTT assay are plotted in the bar charts. The drug concentrations are as labelled by the grey-scale key. The glucose and insulin concentrations and the stages of DM2 that they represent are as labelled beneath the bar charts. Error bars represent 95% confidence intervals. The 3D surface demonstrated that the inhibitory effect of rosiglitazone (100 M) and metformin (20 mM) in HER18 (E) and MCF7 (F) cells was present at all the insulin and glucose concentrations tested. Beginning with the same number of cells, the number of live cells were examined by the MTT assay after culturing for 3 days in DMEM without glucose ϩ 1% FBS with glucose and insulin added at various concentrations.
Fig. 3 Metformin and rosiglitazone induce apoptosis in cancer cells. (A) MiaPaCa2 and HER18 cells were treated with or without the indicated drugs followed by FACS analysis. The vertical axis represents fluorescence due to PI, and the horizontal axis represents fluorescence due to FITC-annexin V binding. The two right quadrants indicate the percentage of apoptotic cells. (B) MiaPaCa2 cells were treated with metformin and rosiglitazone for 24 hrs. The numbers of live (dye-excluding) cells were counted using a haemocytometer after Trypan blue staining. The error bars represent 95% confidence intervals. (C) Immunoblots of MiaPaCa2 cell lysates after control
The combination of gemcitabine with either rosiglitazone or metformin resulted in increased inhibition of pancreatic cancer cells
Because our results above showed that metformin and rosiglitazone activated signalling molecules that are already known to negatively regulate the AKT/mTOR pathway, we suggested that the combination of gemcitabine with either rosiglitazone or metformin could further increase inhibition of pancreatic cancer cells in four combinations of insulin and glucose concentrations mimicking different stages of DM2. As a negative control, we used the combination of exenatide with gemcitabine, which did not result in additional inhibition of MiaPaCa2 cells
. Multiple linear regression analysis of the above MTT data
Fig. 5 The combination of gemcitabine with rosiglitazone increases inhibition of pancreatic cancer cells. The gemcitabine dose-response curves of MiaPaCa2 cells in the presence of different concentrations of exenatide (A), metformin (B) and rosiglitazone (C) are shown as labelled. Data obtained with different combinations of insulin and glucose representing normal, pre-diabetes, overt diabetes and late diabetes are shown from left to right. (D) Evaluation of the combination of gemcitabine with metformin or rosiglitazone on pancreatic cancer cell proliferation. The combination index was evaluated using CalcuSyn for metformin ϩ gemcitabine (triangles) and rosiglitazone ϩ gemcitabine (circles). The log (combination index) -fractional effect plots of the data obtained with different combinations of insulin and glucose representing normal
To further examine the inhibitory effect of the combination of gemcitabine with either rosiglitazone or metformin on pancreatic cancer cells, we then analysed the amount of apoptotic cells under these combinations. MiaPaCa2 cells were treated for 48 hrs with gemcitabine 0.1 M plus rosiglitazone 100 M or metformin 20 mM, followed by FITC-annexin V staining for flow cytometry analysis. (Fig. 4) (Fig. 6A and B) . Increased apoptosis as indicated by specific cleavage of PARP was associated with inhibition of AKT/mTOR signalling by the effect of rosiglitazone on PTEN or the effect of metformin on AMPK (Fig. 6C) . Here, we provide a working model for the action of these drugs on signal mediators in cancer cells in Figure 6(D 
